Outlook Therapeutics (OTLK) Shares Outstanding (Diluted Average) (2016 - 2026)

Outlook Therapeutics (OTLK) has 10 years of Shares Outstanding (Diluted Average) data on file, last reported at $81.8 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $81.8 million, up 165.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.8 million (up 165.06% YoY), and the FY2025 annual result was $34.8 million, up 87.59% from the prior year.
• Shares Outstanding (Diluted Average) advanced to $81.8 million in Q1 2026 per OTLK's latest filing, from $60.2 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $260.3 million in Q4 2023 and troughed at $12.1 million in Q1 2023.
• A 5-year average of $109.9 million and a median of $60.2 million in 2025 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Diluted Average) tumbled 94.1% in 2023, then jumped 165.06% in 2026.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $227.4 million in 2022, then gained by 14.44% to $260.3 million in 2023, then tumbled by 90.69% to $24.2 million in 2024, then soared by 148.43% to $60.2 million in 2025, then jumped by 35.93% to $81.8 million in 2026.
• Business Quant data shows OTLK's Shares Outstanding (Diluted Average) at $81.8 million in Q1 2026, $60.2 million in Q4 2025, and $34.8 million in Q3 2025.